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Abstract
Background: Cervical cancer and its precursor, high-grade cervical intraepithelial neoplasia (CIN2/3), are associated
with persistent high-risk human papillomavirus (HPV) infection. HPV genotype prevalence varies with severity of
cervical lesions, patient age and geographical location. The aim of this study was to investigate HPV genotypes
prevalence and attribution according to the severity of cervical lesions among Chinese women.
Method: A 4-year surveillance study was performed. A total of 1664 female patients were included and their
cervical histological diagnosis consisted of cervical intraepithelial neoplasia grade 1 (CIN1, 376 cases), grade 2 (CIN2,
408 cases), grade 3 (CIN3, 336 cases) and invasive cervical cancers (ICC, 544 cases). HPV genotypes prevalence and
attribution to cervical lesions were calculated and analyzed. The 95% confidence interval (CI) for proportion was
also calculated.
Results: HPV positivity rates increased directly with cervical lesions severity (72.4% for CIN1, 81.4% for CIN2, 88.1%
for CIN3 and 90.4% for ICC). Infections with multiple HPV types were inversely related to cervical lesions severity.
HPV16, 52, 31, 33 and 58 were the most prevalent genotypes in ICC. 49.1% of squamous cell carcinoma, 65.1% of
adenocarcinoma and 12.0–43.3% of cervical intraepithelial neoplasia could be attributed to vaccine-covered high-
risk genotypes (HPV16/18). Inclusion of HPV52 and HPV31 in future vaccines would provide the highest marginal
benefit in protection for individuals residing in this region.
Conclusions: These findings provide information about HPV genotypes in this region which may be important to
target with future vaccination and screening programs.
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Background
Cervical intraepithelial neoplasia (CIN) is a premalignant
lesion that is diagnosed by histology as CIN1, CIN2, or
CIN3. If left untreated, CIN2 or CIN3 (high-grade CIN)
might progress to cervical cancer. There were an esti-
mated 527,600 new cervical cancer cases and 265,700
deaths worldwide in 2012 [1]. It is the second most com-
monly diagnosed cancer and third leading cause of
cancer-induced death among females in less developed
countries [1]. Persistent infection with one or more of
carcinogenic genotypes of human papillomavirus (HPV)
is a high-risk cause for cervical neoplasia [2]. At least 13
distinct high-risk HPV genotypes (HPV16, 18, 31, 33, 35,
39, 45, 51, 52, 56, 58, 59, and 68) have been identified to
be associated with the risk of developing cervical cancer
and defined as “carcinogenic” viral genotypes [3]. Car-
cinogenic HPV genotypes can be detected in more than
90% of cervical cancer specimens and in more than 60%
of CIN tissues [4, 5].
For prevention of HPV infection and the potential de-
velopment of cervical neoplasia, two prophylactic
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vaccines (Cervarix by GlaxoSmithKline and Gardasil by
Merck Sharp and Dohme) are currently available. These
two HPV vaccines potentially provide protection against
two most common HPV genotypes, HPV16 and 18,
which cause approximately 70% of invasive cervical can-
cers worldwide [6]. However, prevalence of the other
carcinogenic HPV genotypes varies markedly by geo-
graphic region [5, 7]. In East Asia, HPV52 and 58 are
more prevalent compared to worldwide [8]. Therefore,
knowledge of the regional prevalence of HPV genotypes
is essential for the development of effective vaccination
as well as preventative screening strategies against cer-
vical cancer.
A recent study performed by our group reported the
HPV prevalence among female outpatients from
Qingdao [9], which is a major city located in eastern
China with a population of over nine million where
prophylactic vaccines against HPV are currently not
available. In the present study, we investigated the preva-
lence and attribution of HPV genotypes to cervical
intraepithelial neoplasia and invasive cancer among
women from this region.
Methods
Study subjects and specimen collection
From January 2012 to December 2015, women who vis-
ited gynecologists or oncologists seeking for further
management of abnormal cervical cytology results in
Qingdao Central Hospital and Qingdao Cancer Hospital,
a tertiary hospital attached to Qingdao University with
1600 beds and a tertiary hospital specializing in oncol-
ogy, were enrolled with informed consents. A participant
was eligible if she (a) was sexually active, (b) was a
gynecological patient, (c) was no previously miscarriage
nor presently pregnant, (d) had not undergone a total
hysterectomy, and (e) agreed to receive HPV genotyping
and cervical histopathology evaluation. A cervical scrape
sample was collected for HPV genotyping. Biopsy-
confirmed histopathologic findings were used to define
the status of cervical neoplasia. All biopsy samples were
taken by a gynecologist according to guidelines from
International Agency for Research on Cancer, WHO
[10]. All procedures of this study were approved by Re-
search Ethics Boards at Qingdao Central Hospital Affili-
ated to Qingdao University (Ethics 2013 No. 023), in
accordance with the ethical standards of the Declaration
of Helsinki.
HPV genotyping and cervical histopathology
Cervical scrape samples were stored in a specimen
transport medium. DNA extraction, amplification and
hybridization were performed using an HPV genotyping
kit (Yaneng Biotech, Shenzhen, China) according to the
manufacturer’s instructions. The HPV DNA chip in the
kit contained 23 type-specific probes that recognize 18
high-risk (16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59,
66, 68, 73, 82 and 83) and 5 low-risk HPV genotypes (6,
11, 42, 43 and 81). PCR amplifications were performed
in a T100 Thermal Cycler (Bio-Rad, USA) with the fol-
lowing parameters: enzyme activation at 50 °C for
15 min, initial denaturation at 95 °C for 10 min, followed
by 10 cycles of 94 °C for 10 s, 42 °C for 90 s and 72 °C
for 30 s, followed by 30 cycles of 94 °C for 10 s, 46 °C
for 60 s and 72 °C for 20 s, ending with a final extension
at 72 °C for 5 min. The PCR product (25 μl) was dena-
tured at 95 °C for 10 min and immediately chilled on
ice. Then, the HPV DNA hybridization reaction was per-
formed on an automatic analyzer according to the man-
ufacturer’s instructions. The hybridization procedure
was presented in Additional file 1: Figure S1. The final
results were obtained by colorimetric change on the chip
under direct visualization. HPV negative and positive
controls, provided in the kit, were simultaneously de-
tected in every test.
The biopsy specimens obtained from the subjects were
fixed by formalin, embedded in paraffin and stained with
hematoxylin-eosin for histopathology in the pathology la-
boratory at Qingdao Central Hospital. Cervical histological
diagnosis of the specimens was reported only when three
different pathologists, from Qingdao Central Hospital and
Qingdao Cancer Hospital, agreed with each other. Path-
ology results were classified into cervical intraepithelial
neoplasia grade 1 (CIN1), CIN grade 2 (CIN2), CIN grade
3 (CIN3) and invasive cervical cancer (ICC) according to
cervical lesions classification criteria [11].
Statistical analysis
Frequencies of clinical data were calculated. The preva-
lence and attribution rates of HPV genotypes were calcu-
lated according to a previous method [8]. Crude
prevalence was estimated by analyzing all studied cases as
the denominator for every disease grade. The relative dis-
tribution for each disease grade was calculated only using
the HPV positive samples as the denominator. The attri-
bution of an HPV genotype to certain disease grade was
calculated as follows: (percentage of samples with single-
type infection) + (percentage of samples with multiple-
type infection multiplied by attribution factor). The “attri-
bution factor” for each HPV genotype was calculated
based on the formula “number of samples with single-type
infection of the HPV genotype concerned divided by the
number of samples with single-type infection of any HPV
genotype in that disease category”. The 95% confidence
interval (CI) for proportion was calculated by the Wilson
score method [12]. Differences in HPV positivity rates and
proportions of multiple-type HPV infections between dis-
ease categories were assessed by Pearson’s χ2 test and p <
0.05 was considered significant.
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Results
HPV infection according to cervical pathology status
According to the inclusive criteria, a total of 1664
women received HPV genotyping and cervical histo-
pathology evaluation. Their cervical pathology status
were as follows: 376 cases of CIN1, 408 cases of
CIN2, 336 cases of CIN3, 440 cases of squamous cell
carcinoma (SCC) and 104 cases of adenocarcinoma.
HPV positivity rates and the proportion of single-
and multiple-type infection for each cervical path-
ology status are presented in Table 1. HPV positivity
rates of CIN1, CIN2, CIN3 and SCC samples were
72.4, 81.4, 88.1 and 94.5%, respectively, which in-
creased directly with severity of cervical lesions. Fur-
ther, the HPV positivity rate of CIN1 group was
significantly lower than that of invasive cervical can-
cer group (p = 6.36 × 10-13). The HPV positivity rate of
adenocarcinoma group was significantly lower than squa-
mous cell carcinoma group (p = 2.13 × 10-11). In addition,
patients with lower grade cervical lesions (CIN1, 42.6%)
displayed a higher frequency of multiple-type HPV infec-
tions compared with those suffering from higher grade
cervical lesions (CIN2 and CIN3, 29.3%, p = 9.59 × 10-5)
and invasive cancers (15.4%, p = 1.05 × 10-16).







Multiple-type infection no. (%)
Two HPV genotypes Three HPV genotypes Four or more HPV genotypes
Cervical intraepithelial neoplasia (CIN)
CIN grade 1 (376) 272 (72.4) 156 (41.5) 68 (18.1) 36 (9.6) 12 (3.2)
CIN grade 2 (408) 332 (81.4) 208 (51.0) 80 (19.6) 24 (5.9) 20 (4.9)
CIN grade 3 (336) 296 (88.1) 236 (70.2) 40 (11.9) 20 (6.0) 0
Invasive cervical cancer
Squamous cell carcinoma (440) 416 (94.5) 348 (79.1) 60 (13.6) 8 (1.8) 0
Adenocarcinoma (104) 76 (73.1) 68 (65.4) 8 (7.7) 0 0
Fig. 1 Relative distribution of HPV genotypes among different grades of cervical intraepithelial neoplasia (a) and invasive cervical cancers (b).
Each kind of genotype was counted separately in cases with multiple-type HPV infections. The positivity rates of genotypes were calculated using
the number of HPV positive samples in each disease grade as the denominator. CIN1, cervical intraepithelial neoplasia grade 1; CIN2, CIN grade 2;
CIN3, CIN grade 3. SCC, squamous cell carcinoma
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Table 2 Prevalence and attribution of all HPV genotypes according to cervical pathology status
HPV
Geno-types
Crude prevalence and attribution in % (95% confidence interval)
Squamous cell carcinoma (440) Adeno-carcinoma (104) CIN3 (336) CIN2 (408) CIN1 (376)
HPV16 Prevalence 48.2 (43.5–52.8) 23.1 (16.0–32.0) 47.6 (42.3–53.0) 41.2 (36.5–46.0) 21.3 (17.4–25.7)
Attribution 44.6 (40.0–49.3) 20.3 (13.7–29.0) 43.3 (38.1–48.6) 30.7 (26.4–35.4) 9.9 (7.3–13.3)
HPV52 Prevalence 18.2 (14.9–22.1) 11.5 (6.7–19.1) 21.4 (17.4–26.1) 21.6 (17.9–25.8) 23.4 (19.4–27.9)
Attribution 15.2 (12.1–18.8) 4.2 (1.7–10.0) 11.1 (8.2–14.9) 14.1 (11.0–17.8) 18.8 (15.2–23.1)
HPV31 Prevalence 10.0 (7.5–13.2) 0.0 (0.0–3.6) 17.9 (14.1–22.3) 12.7 (9.9–16.3) 10.6 (7.9–14.2)
Attribution 3.9 (2.4–6.1) 0.0 (0.0–3.6) 10.6 (7.8–14.4) 8.6 (6.2–11.7) 3.8 (2.3–6.2)
HPV33 Prevalence 8.2 (6.0–11.1) 0.0 (0.0–3.6) 6.0 (3.9–9.0) 12.7 (9.9–16.3) 9.6 (7.0–13.0)
Attribution 1.1 (0.5–2.6) 0.0 (0.0–3.6) 3.7 (2.2–6.3) 2.4 (1.3–4.4) 5.9 (3.9–8.7)
HPV58 Prevalence 8.2 (6.0–11.1) 0.0 (0.0–3.6) 4.8 (3.0–7.6) 8.8 (6.4–12.0) 10.6 (7.9–14.2)
Attribution 3.8 (2.4–6.0) 0.0 (0.0–3.6) 3.7 (2.1–6.2) 3.2 (1.9–5.4) 3.8 (2.3–6.2)
HPV51 Prevalence 3.6 (2.3–5.8) 0.0 (0.0–3.6) 6.0 (3.9–9.0) 5.9 (4.0–8.6) 8.5 (6.1–11.8)
Attribution 2.7 (1.6–4.7) 0.0 (0.0–3.6) 0.0 (0.0–1.1) 0.0 (0.0–0.9) 0.0 (0.0–1.0)
HPV53 Prevalence 7.3 (5.2–10.1) 0.0 (0.0–3.6) 0.0 (0.0–1.1) 7.8 (5.6–10.9) 8.5 (6.1–11.8)
Attribution 5.6 (3.8–8.2) 0.0 (0.0–3.6) 0.0 (0.0–1.1) 4.2 (2.6–6.6) 0.0 (0.0–1.0)
HPV59 Prevalence 2.7 (1.6–4.7) 0.0 (0.0–3.6) 0.0 (0.0–1.1) 6.9 (4.8–9.7) 4.3 (2.6–6.8)
Attribution 2.7 (1.5–4.7) 0.0 (0.0–3.6) 0.0 (0.0–1.1) 0.0 (0.0–0.9) 3.3 (1.9–5.6)
HPV56 Prevalence 0.0 (0.0–0.9) 0.0 (0.0–3.6) 6.0 (3.9–9.0) 2.0 (1.0–3.8) 0.0 (0.0–1.0)
Attribution 0.0 (0.0–0.9) 0.0 (0.0–3.6) 6.0 (3.9–9.1) 0.0 (0.0–0.9) 0.0 (0.0–1.0)
HPV35 Prevalence 0.9 (0.4–2.3) 0.0 (0.0–3.6) 0.0 (0.0–1.1) 0.0 (0.0–0.9) 6.4 (4.3–9.3)
Attribution 0.0 (0.0–0.9) 0.0 (0.0–3.6) 0.0 (0.0–1.1) 0.0 (0.0–0.9) 0.0 (0.0–1.0)
HPV18 Prevalence 4.5 (3.0–6.9) 46.2 (36.9–55.7) 1.2 (0.5–3.0) 0.0 (0.0–0.9) 2.1 (1.1–4.1)
Attribution 4.5 (2.9–6.9) 44.8 (35.6–54.3) 0.0 (0.0–1.1) 0.0 (0.0–0.9) 2.1 (1.1–4.1)
HPV45 Prevalence 0.0 (0.0–0.9) 0.0 (0.0–3.6) 0.0 (0.0–1.1) 2.0 (1.0–3.8) 0.0 (0.0–1.0)
Attribution 0.0 (0.0–0.9) 0.0 (0.0–3.6) 0.0 (0.0–1.1) 0.0 (0.0–0.9) 0.0 (0.0–1.0)
HPV68 Prevalence 0.0 (0.0–0.9) 0.0 (0.0–3.6) 0.0 (0.0–1.1) 0.0 (0.0–0.9) 4.3 (2.6–6.8)
Attribution 0.0 (0.0–0.9) 0.0 (0.0–3.6) 0.0 (0.0–1.1) 0.0 (0.0–0.9) 0.0 (0.0–1.0)
HPV73 Prevalence 0.0 (0.0–0.9) 0.0 (0.0–3.6) 1.2 (0.5–3.0) 0.0 (0.0–0.9) 0.0 (0.0–1.0)
Attribution 0.0 (0.0–0.9) 0.0 (0.0–3.6) 0.0 (0.0–1.1) 0.0 (0.0–0.9) 0.0 (0.0–1.0)
HPV82 Prevalence 0.0 (0.0–0.9) 0.0 (0.0–3.6) 0.0 (0.0–1.1) 4.9 (3.2–7.4) 3.2 (1.8–5.5)
Attribution 0.0 (0.0–0.9) 0.0 (0.0–3.6) 0.0 (0.0–1.1) 0.0 (0.0–0.9) 0.0 (0.0–1.0)
HPV66 Prevalence 0.0 (0.0–0.9) 0.0 (0.0–3.6) 0.0 (0.0–1.1) 0.0 (0.0–0.9) 6.4 (4.3–9.3)
Attribution 0.0 (0.0–0.9) 0.0 (0.0–3.6) 0.0 (0.0–1.1) 0.0 (0.0–0.9) 1.2 (0.5–2.9)
HPV39 Prevalence 0.0 (0.0–0.9) 0.0 (0.0–3.6) 0.0 (0.0–1.1) 0.0 (0.0–0.9) 2.1 (1.1–4.1)
Attribution 0.0 (0.0–0.9) 0.0 (0.0–3.6) 0.0 (0.0–1.1) 0.0 (0.0–0.9) 0.0 (0.0–1.0)
HPV83 Prevalence 0.0 (0.0–0.9) 0.0 (0.0–3.6) 0.0 (0.0–1.1) 0.0 (0.0–0.9) 0.0 (0.0–1.0)
Attribution 0.0 (0.0–0.9) 0.0 (0.0–3.6) 0.0 (0.0–1.1) 0.0 (0.0–0.9) 0.0 (0.0–1.0)
HPV81 Prevalence 0.0 (0.0–0.9) 0.0 (0.0–3.6) 0.0 (0.0–1.1) 0.0 (0.0–0.9) 1.1 (0.4–2.7)
Attribution 0.0 (0.0–0.9) 0.0 (0.0–3.6) 0.0 (0.0–1.1) 0.0 (0.0–0.9) 0.0 (0.0–1.0)
HPV6 Prevalence 0.0 (0.0–0.9) 0.0 (0.0–3.6) 0.0 (0.0–1.1) 0.0 (0.0–0.9) 0.0 (0.0–1.0)
Attribution 0.0 (0.0–0.9) 0.0 (0.0–3.6) 0.0 (0.0–1.1) 0.0 (0.0–0.9) 0.0 (0.0–1.0)
HPV43 Prevalence 0.0 (0.0–0.9) 0.0 (0.0–3.6) 0.0 (0.0–1.1) 0.0 (0.0–0.9) 0.0 (0.0–1.0)
Attribution 0.0 (0.0–0.9) 0.0 (0.0–3.6) 0.0 (0.0–1.1) 0.0 (0.0–0.9) 0.0 (0.0–1.0)
HPV11 Prevalence 0.0 (0.0–0.9) 0.0 (0.0–3.6) 0.0 (0.0–1.1) 0.0 (0.0–0.9) 0.0 (0.0–1.0)
Attribution 0.0 (0.0–0.9) 0.0 (0.0–3.6) 0.0 (0.0–1.1) 0.0 (0.0–0.9) 0.0 (0.0–1.0)
Zhang et al. BMC Infectious Diseases  (2017) 17:107 Page 4 of 9
Relative distribution of HPV genotypes according to
cervical pathology status
Detailed HPV genotypes distribution according to the
severity of cervical lesions was also investigated. Each
kind of genotype was counted separately in cases with
multiple-type HPV infections. As shown in Fig. 1, distri-
bution of the 11 most frequent genotypes in this study
was presented. Top five most frequent genotypes among
high-grade cervical lesions (both CIN2 and CIN3) were
HPV16 (336/37.7%), HPV52 (160/17.9%), HPV31 (112/
12.6%), HPV33 (72/8.1%) and HPV58 (52/5.8%). In con-
trast, the genotypes distribution was shown to be differ-
ent in CIN1, where HPV52 was the most frequent
genotype detected (88/19.1%), followed by HPV16 (80/
17.4%) and HPV58 (40/8.7%) (Fig.1a). As shown in
Fig.1b, among squamous cell carcinoma cases, HPV16
was the most common genotype (212/43.1%), followed
by HPV52 (80/16.3%), HPV31 (44/8.9%) and HPV58
(36/7.3%). As for adenocarcinoma, only three kinds of
genotypes were detected and HPV18 was the most
prevalent type (48/57.1%), followed by HPV16 (24/
28.6%) and HPV52 (12/14.3%).
Attribution of HPV genotypes in cervical lesions
The crude prevalence and attribution rates of all HPV
genotypes to each cervical pathology status were pre-
sented in Table 2. The majority (44.6%) of squamous cell
carcinoma was attributed to HPV16. Subsequently, 15.2,
5.6 and 4.5% of squamous cell carcinoma were attributed
to HPV52, HPV53 and HPV18, respectively. In contrast,
the majority (44.8%) of adenocarcinoma was attributed
to HPV18 and the following genotypes were HPV16
(20.3%) and HPV52 (4.2%).
HPV16 also accounted for the majority of high-grade
lesions (CIN3 and CIN2) with attribution rate of 43.3
and 30.7%, respectively. HPV52 was the following geno-
type, which attributed to 11.1 and 14.1% of CIN3 and
CIN2, respectively (Table 2). In contrast, HPV16 was
not the most common genotype found in CIN1. Either
by crude prevalence rate or attribution rate, HPV52
ranked higher than HPV16 in CIN1.
The cumulative attribution rates of 11 high-risk HPV
genotypes to invasive cervical cancer and cervical intrae-
pithelial neoplasia were presented in Figs. 2 and 3, re-
spectively. The two high-risk types (HPV16 and HPV18)
attributed to 49.1% of squamous cell carcinoma (Fig.2a),
65.1% of adenocarcinoma (Fig.2b), 43.3% of CIN3
(Fig.3a), 30.7% of CIN2 (Fig.3b) and 12.0% of CIN1
(Fig.3c) cases. The subsequent genotype, HPV52,
brought the biggest marginal increase with 15.2% for
squamous cell carcinoma (Fig.2a), 11.1% for CIN3,
14.1% for CIN2 and 18.8% for CIN1 lesions.
Age-specific prevalence of cervical lesions and cancers
All 1664 patients involved were classified into five
groups according to age (≤25, 26–35, 36–45, 46–55,
Fig. 2 Cumulative attribution rates of high-risk HPV genotypes to invasive cervical cancer. a Squamous cell carcinoma; b adenocarcinoma. Marginal
attribution rates conferred by individual HPV genotypes are italicized. Bold numbers represent cumulative attribution rates
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≥56) and age-specific prevalence of cervical lesions and
cancers was presented in Fig. 4. As shown in Fig. 4,
80.8% of the patients with adenocarcinoma and 62.7%
with SCC were more than 46 years old. Moreover, 30.6%
of the patients with high-grade cervical lesions (CIN2
and CIN3) were younger than 35.
Discussion
Data of HPV prevalence and attribution according to
cervical pathology status presented in this study may
provide guidance for HPV vaccination program and pre-
ventative strategies against cervical cancer in this region
of China. Among the involved female patients, HPV
positivity rates increase directly with the cervical lesion
severity, which is consistent with some previous studies
from different regions of China [8, 13–15]. The overall
HPV prevalence among ICC patients reaches 90.4% in
this study, which is consistent with the worldwide HPV
prevalence in cervical cancers, ranging from 86 to 94%
[4, 16, 17]. In this study, single-type HPV infection is
more prevalent in high-grade CIN and ICC patients than
in low-grade CIN and the single-type HPV positivity
rates also increase directly with the cervical lesion sever-
ity, which is consistent with a previous study from
Fig. 3 Cumulative attribution rates of high-risk HPV genotypes to cervical intraepithelial neoplasia. a CIN grade 3; b CIN grade 2; c CIN grade 1.
Marginal attribution rates conferred by individual HPV genotypes are italicized. Bold numbers represent cumulative attribution rates
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Beijing, China [18]. In this study, HPV infections are all
high-risk genotypes among the high-grade CIN and ICC
patients and the most prevalent genotypes are HPV16,
52, 31, 33 and 58. Another study in China reported that
the most common HPV genotypes in high-grade CIN
and cervical cancers are HPV16, 58, 31, 52, 33 and
HPV16, 33, 18, 52, 58, respectively [13]. A multiple-
center study in Beijing reported that HPV16, 58, 33, 56,
and 31 are the most prevalent genotypes in cervical le-
sions [19]. It’s observed from these results that HPV16,
52, 31, 33, 58, 56 and 18 are prevalent genotypes among
women with cervical lesions in China. A worldwide
meta-analysis also confirmed that eastern Asia exhibits
an HPV genotype distribution pattern distinct from the
other areas of the world, a relatively high contribution of
HPV52 and 58 to cervical lesions [20]. In this study,
HPV18 was the most prevalent genotype among adeno-
carcinoma patients. This is in accordance with several
studies focusing on cervical adenocarcinoma. HPV18
highly correlated to adenocarcinoma worldwide includ-
ing China [21, 22]. Furthermore, HPV18, 16 and 45 have
been reported to be the most prevalent genotypes in
adenocarcinoma worldwide [20, 23]. However, in the
present study, the presence of HPV52 instead of HPV45
in adenocarcinoma was observed and consistent with
studies in eastern Asia [8, 20].
In this study, we found a high rate of young women
with high grade cervical lesions (CIN2 and CIN3). 30.6%
of patients with high-grade cervical lesions were younger
than 35. Notably, 5.0% of patients with high-grade cer-
vical lesions were even younger than 25, which is higher
than that from a neighboring area of this region (3.4%)
[24]. Therefore, for this region, vaccination program and
preventative screening strategies against cervical cancer
are expected to pay more attention to young women.
Furthermore, an approach adopted from previous
studies [8, 25], which assumed a fractional attribution of
individual HPV genotypes found simultaneously in a le-
sion, was applied to the current data. It was estimated
that the current HPV16/18-based vaccines would pro-
tect against 49.1% of squamous cell carcinoma, 65.1% of
adenocarcinoma and 12.0–43.3% of CINs. In this region,
HPV52 and HPV31 were determined to be the next
common types in contributing to squamous cell carcin-
oma and CINs, which is in accordance with several stud-
ies in eastern Asia including China [20, 26, 27].
Therefore, for this region of China, vaccination program
and preventative strategies against cervical cancer are
expected to pay attention to HPV52, 31, 58 and 33 along
with vaccine preventable HPV 16 and 18. The two
prophylactic vaccines mentioned, proved to be effective
in preventing cervical cancer, are available in many
countries worldwide except mainland China. Even if the
2-valent (HPV16 and 18) or 4-valent (HPV6, 11, 16 and
18) is going to be commercial available in mainland
China, the demand for vaccines against more particular
genotypes is still strong. The newcome 9-valent HPV
vaccine may provide more protections against cervical
lesions for women in this region of China.
In this present work, the “attribution factor” of each
HPV genotype was calculated and cumulative attribution
rates of prevalent high-risk HPV genotypes were pre-
sented. The 95% confidence interval (CI) for proportion
was also calculated. These methods have been rarely used
to analyze HPV infections in mainland China before.
There are still some limitations in this study. The total
number of samples involved in this study is not large.
Multi-center study, including over three tertiary hospitals,
may be more valuable. In addition, interactions between
different HPV genotypes still need further investigation.
Fig. 4 Age-specific prevalence of cervical lesions and cancers
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Conclusions
This study presented HPV genotypes prevalence and
attribution data among female patients with cervical
lesions in this area, where the planning of HPV vaccin-
ation should be taken into account the prevalent geno-
types of HPV16, HPV52, HPV31, HPV58 and HPV33.
These data added new evidence that eastern Asia, in-
cluding eastern China, exhibited an HPV genotype dis-
tribution pattern distinct from other parts of the world.
Our results also could provide necessary reference for
formulating a regional HPV-based screening strategy in
the future.
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